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Background: Pancreatic ductal adenocarcinoma (PDAC) is characterised by extensive matrix deposition 
that has been implicated in impaired drug delivery and therapeutic resistance. Secreted protein acidic 
and rich in cysteine (SPARC) is a matricellular protein that regulates collagen deposition and is highly 
upregulated in the activated stroma subtype with poor prognosis in PDAC patients. 
Methods: Kras G12D ;p48-Cre; SPARC −/ − (KC- SPARC −/ − ) and Kras G12D ;p48-Cre; SPARC WT (KC- SPARC WT ) 
were generated and analysed at different stages of carcinogenesis by histological grading, immunohisto- 
chemistry for epithelial and stromal markers, survival and preclinical analysis. Pharmacokinetic and phar- 
macodynamic studies were conducted by liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
and immunohistochemistry following gemcitabine treatment (100 mg/kg) in vivo. 
Findings: Global genetic ablation of SPARC in a Kras G12D driven mouse model resulted in signiﬁcantly re- 
duced overall and mature collagen deposition around early and advanced pancreatic intraepithelial neo- 
plasia (PanIN) lesions and in invasive PDAC ( p < .001). However, detailed pathological scoring and molec- 
ular analysis showed no effects on PanIN to PDAC progression, vessel density (CD31), tumour incidence, 
grading or metastatic frequency. Despite comparable tumour kinetics, ablation of SPARC resulted in a sig- 
niﬁcantly shortened survival in KC- SPARC −/ − mice (280 days versus 485 days, p < .03, log-rank-test ). Using 
LC-MS/MS, we show that SPARC dependent collagen deposition does not affect intratumoural gemcitabine 
accumulation or immediate therapeutic response in tumour bearing KC- SPARC WT and KC- SPARC −/ −mice. 
Interpretation: Global SPARC ablation reduces the collagen-rich microenvironment in murine PDAC. More- 
over, global SPARC depletion did not affect tumour growth kinetics, grading or metastatic frequency. No- 
tably, the dense-collagen matrix did not restrict access of gemcitabine to the tumour. These ﬁndings may 
have direct translational implications in clinical trial design. 
© 2019 The Authors. Published by Elsevier B.V. 
This is an open access article under the CC BY-NC-ND license. 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
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t  Research in context 
Evidence before this study 
Pancreatic ductal adenocarcinoma (PDAC) features pro- 
nounced desmoplasia with abundant extracellular matrix 
(ECM) components such as collagen and hyaluronic acid that 
promote tumourigenesis and impede drug delivery and re- 
sponse. Secreted protein acidic and rich in cysteine (SPARC) 
is a matricellular protein that is expressed in bone, testis and 
connective tissues. SPARC has been functionally implicated in 
wound healing and collagen deposition. Interestingly, SPARC 
is highly expressed by peritumoural ﬁbroblasts in PDAC. Re- 
cent high-throughput sequencing technologies have identi- 
ﬁed SPARC as a marker for the activated stroma subtype in 
human PDAC that correlates with poor prognosis. However, 
SPARC has not been investigated in genetically engineered 
mouse models at different precursor stages of PDAC to de- 
termine its contribution to progression and therapeutic resis- 
tance. 
Added value of this study 
The present study provides evidence that global SPARC 
ablation results in signiﬁcantly reduced collagen deposi- 
tion around PanIN lesions and tumours in the Kras G12D 
mouse model. Notably, SPARC dependent collagen deposition 
did not affect pancreatic intraepithelial neoplasia (PanIN) to 
PDAC progression, vascularity, proliferation, apoptosis rate, or 
metastatic frequency. Despite a lower tumour frequency in 
KC- SPARC −/ − mice, median survival was signiﬁcantly short- 
ened compared to KC- SPARC WT . This phenotype was likely 
caused by more severe clinical symptoms such as diar- 
rhoea, jaundice and ascites upon tumour induction in KC- 
SPARC −/ −. Despite the prevailing hypothesis that the ECM 
matrix impedes drug delivery and eﬃcacy in PDAC, liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) and 
immunohistochemistry revealed comparable pharmacokinetic 
and pharmacodynamics characteristics for gemcitabine in KC- 
SPARC WT and KC- SPARC −/ − mice. 
Implications of all the available evidence 
We have investigated the role of global SPARC deple- 
tion during different stages of pancreatic tumourigenesis. Our 
ﬁndings show that global SPARC depletion results in com- 
parable PanIN and tumour growth kinetics despite a more 
severe clinical phenotype in KC- SPARC −/ − mice. Furthermore, 
our data contradict the prevailing hypothesis that the dense- 
collagen matrix restricts access of gemcitabine to the tumour. 
Thus, our ﬁndings may have direct translational implications 
in clinical trial design. 
1. Introduction 
Histologically, PDAC is characterised by abundant stroma that
harbours inﬂammatory cells (e.g. myeloid cells), cancer-associated
ﬁbroblast (CAFs), and large amounts of extracellular matrix (ECM)
components, in particular collagen and hyaluronic acid [ 1, 2 ]. The
extensive tumour stroma was shown to contribute towards tu-
mour progression, therapeutic resistance and poor prognosis in
PDAC [ 3, 4 ]. However, it is still unclear which components of the
tumour stroma contribute to disease progression, and whether this
is dependent on deposition of certain ECM components during
pancreatic intraepithelial neoplasia (PanIN)-PDAC progression. To
this end, several preclinical experiments suggest that pharmaco-
logical depletion or remodelling of acellular components such asyaluronic acid and collagen increases delivery of and response to
ntineoplastic agents [ 5–10 ]. On the other hand, recent data show
o correlation between intra-tumoural gemcitabine concentrations
nd overall survival in a preclinical study using genetically engi-
eered mice thus casting doubt on the biophysical drug barrier
ypothesis [ 11 ]. Furthermore, the failure of numerous clinical tri-
ls using anti-stromal agents (e.g. sonic hedgehog inhibitors, ma-
rix metalloproteinase, MMP inhibitors) has further dampened the
nitial euphoria of the stromal depletion strategy and fuelled scep-
icism whether the stromal barrier hypothesis is correct [ 12 ]. 
SPARC is an important matricellular protein that is overex-
ressed in peritumoural ﬁbroblasts and has been associated with
ollagen deposition and the activated stroma subtype in PDAC
 13, 14 ]. High expression of SPARC in peritumoural ﬁbroblasts is as-
ociated with a poor prognosis in PDAC patients [ 15 ]. Moreover,
PARC was proposed as a negative predictive factor for the treat-
ent with gemcitabine [ 16 ]. Whether these clinical ﬁndings are
ausally related to SPARC or just associated with a more desmo-
lastic phenotype remains unanswered. Moreover, preclinical data
rom different mouse models show conﬂicting results regarding the
ole of SPARC in PDAC [ 17–21 ]. 
To investigate the role of SPARC in PDAC progression, drug de-
ivery and response, we employed the LSL-Kras G12D/+ ; p48 -Cre (KC)
ouse model that develops PanIN lesions at 3–4 months of age
nd progresses to invasive PDAC after a latency of 12–15 months
 22 ]. Progression to PDAC is accompanied by the development of a
ronounced tumour microenvironment (TME) in which ECM com-
onents such as collagen and hyaluronic acid increasingly accu-
ulate. To test the potential of SPARC as a biomarker for gem-
itabine treatment, we used a recently established and validated
iquid chromatography-mass spectrometry/mass spectrometry (LC-
S/MS) assay [ 23–25 ], the most sensitive method to quantify gem-
itabine metabolites in small tissue biopsies, and assess response
n pancreatic tumour tissues from KC- SPARC −/ − and KC- SPARC WT 
ice. 
. Material and methods 
.1. Genetically engineered mouse models 
SPARC −/ − mice (B6;129S- Sparc tm1we /J) were purchased from
harles River (Margate, UK) [ 26 ]. LSL-Kras G12D ; p48-Cre (KC) mice
129Sv and C57BL/6) were obtained from the Tuveson group [ 22 ].
C mice develop acinar to ductal metaplasia (ADMs) and PanINs at
n early age and slowly progress to advanced and metastatic PDAC
fter a long latency (usually > 12 months) [ 22 ]. The model recapit-
lates the full spectrum of histopathological and clinical features
f human PDAC. Kras G12D and p48-Cr e mice were both crossed
ith SPARC −/ − mice, and subsequent crossing of Kras G12D ; SPARC +/ −
ice with p48-Cre ;SPARC +/ − mice resulted in KC- SPARC W T and KC-
PARC −/ − mice with a mixed background (129SvJ and C57BL/6). All
nimal experiments were carried out using protocols approved by
he Institutional Animal Care and Use Committee at the University
edical Centre Göttingen. Mice were housed at a 12 h light, 12 h
ark rhythm. 
.2. Therapeutic intervention and survival studies 
KC- SPARC WT and KC- SPARC −/ − mice were subjected to treatment
fter detection of pancreatic tumours of at least 0.5 cm as de-
cribed before [ 27 ]. For pharmacokinetic studies, 12–15 months old
C- SPARC WT and KC- SPARC −/ − mice were treated with gemcitabine
100 mg/kg body weight) once. Gemcitabine hydrochloride (Sigma,
SA) was resuspended in sterile normal saline at 10 mg/ml. All tis-
ues were harvested 2 h after the last gemcitabine dose for fur-
her analysis as previously described [ 25 ]. The 2 h time point was
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e  reviously found to be the Tmax for intratumoural dFdCTP in KPC
ancreatic tumours [ 23, 25 ]. For survival analysis, endpoint criteria
or KC- SPARC WT and KC- SPARC −/ − were deﬁned as 20% body weight
oss, general morbidity, lethargy, lack of social interaction or devel-
pment of ascites. 
.3. Liquid chromatography-mass spectrometry/mass spectrometry 
LC-MS/MS) 
Fresh frozen tumour samples were homogenised and extracted
n 50% acetonitrile with 25 μg/ml tetrahydrouridine (THU, Cal-
iochem). Samples were then prepared and analysed in one batch
s previously described [ 23, 24 ]. Brieﬂy, a standard curve was gen-
rated using standards of known concentration of each analyte
piked into blank tumour homogenate, and quality control sam-
les (at lower limit of quantiﬁcation, low, medium and high con-
entration) were included at the beginning and end of the run
o conﬁrm batch acceptance. LC-MS/MS for gemcitabine (dFdC),
FdU and dFdCTP was performed using PGC Hypercarb columns
Thermo Fisher Scientiﬁc, UK) and a Thermo Scientiﬁc TSQ Vantage
riple stage quadrupole mass spectrometer with Vanquish Quater-
ary UPLC, data acquired with LC Quan 2.5.6. 
.4. Cell lines 
Murine CAFs and cancer cells were isolated from freshly iso-
ated pancreata derived from KC- SPARC WT and KC- SPARC −/ − mice
s previously described and maintained in DMEM (Invitrogen, USA)
10% FBS and 1% non-essential amino acids. (Thermo Fisher, USA).
 11 ]. The following human pancreatic cancer cell lines were used:
3.6pl, Panc-1, Capan-1, Bxpc-3. Two immortalised human pancre-
tic stellate cell lines were used as previously described and ab-
reviated PSC1 [ 28 ], and PSC2 [ 29 ]. 
.5. Western blot analysis 
Western blot analysis was performed as previously described
 11 ]. The following primary antibodies were used: Hsp90 (Cell
ignaling, USA, #4875, RRID: AB_2233331), SPARC (R&D Systems,
SA #AF942, RRID: AB_2286625), mAb SPARC (D10F10, Cell Signal-
ng; RRID: AB_10860770), and collagen I (Abcam, ab21286, RRID:
B_446161). Membranes were incubated with secondary HRP-
ntibodies (Jackson ImmunoResearch, USA) and developed using
hemiluminescence substrate Plus-ECL (PerkinElmer Inc., USA) and
rotein bands were detected at the ChemiDoc TM XRS+ imaging sys-
em (Bio-Rad Laboratories GmbH, Germany) using Image Lab Soft-
are (version 5.2.1, RRID: SCR 014210). 
.6. Histological examination and laser ﬂuorescence microscopy 
Tissues were ﬁxed in 10% neutral buffered formalin (Sigma)
or 24 h and transferred to 70% ethanol. Tissues were embedded
n paraﬃn, and 3–5 μm sections were processed for H&E staining,
mmunohistochemistry and co-immunoﬂuorescence using standard 
rotocols as previously described [ 30 ]. The following antibodies
nd kits were used: SPARC (R&D Systems, AF942, 1:100, RRID:
B_2286625), α-SMA (Dako, Clone 1A4, 1:250, RRID: AB_2335694),
C3 (Cell signaling, 9664L, 1:100, RRID: AB_2070042) and Ki67
Thermo Scientiﬁc, RM-9106, 1:200, RRID: AB_2341197), CD31 (BD
iosciences, 553370, 1:100, RRID: AB_394816). Pictures were taken
ith 40 × magniﬁcation with an Olympus DP27 camera and the
lympus cellSens Entry 1.12 software. 
.7. Extracellular matrix stains 
The following reagents were used for special extracellular ma-
rix stains: Picrosirius Red Stain Kit (Polysciences Inc., Cat. 24901-50), Masson trichrome staining kit (Polysiences Inc., Cat. 25088-
), Weigert’s iron hematoxylin kit (Sigma) and hyaluronic acid
inding protein (Calbiochem, Cat. 385911). The stainings were per-
ormed according to standard protocols on formalin ﬁxed, paraf-
n embedded mouse tissues. Images were acquired as described
bove. 
.8. Methods of quantiﬁcation 
.8.1. Automated quantiﬁcation 
Automated quantiﬁcation of picrosirius, hyaluronic acid and α-
MA staining area was conducted by using Fiji/ImageJ (Fiji, RRID:
CR 002285) applying a low threshold to account for background
taining of necrotic tumour areas. For Masson trichrome, CD31 and
erovici stainings, automated quantiﬁcation was performed using
he Ariol SL-50 and Aperio XT automated scanning system and
magescope 10 software (Leica Biosystems, Germany) as described
reviously [ 31 ]. 
.8.2. Manual quantiﬁcation 
The following IHC data were manually quantiﬁed by count-
ng positive stained cells for CC3 and Ki67 at least 5 HPFs (40 ×
er slide) divided by the number of all nuclei as determined
y ImageJ. PanIN and ADM lesions from early (3–4 months old)
nd late (7–8 months old) KC- SPARC WT and KC- SPARC −/ − mice
ere semi-quantitatively scored by an expert pancreas patholo-
ist (B.S.) with score 0: normal tissue/no PanIN/no ADM, score 1:
 30% ADMs/PanINs of total pancreas tissue area, score 2: 30–70%
DMs/PanINs, score 3: > 70% ADMs/PanINs of total tissue area. For
etastasis quantiﬁcation, 5 serial H&E liver sections were quanti-
ed for metastatic burden. Liver metastases ranging from 100 to
00 μm were arbitrarily considered micro-metastases, > 200 μm as
acro-metastases. Each macro-metastasis was multiplied by 3 for
he ﬁnal metastatic score to account for the different size. 
.9. Statistical analysis 
Data are presented as mean ± SD. Statistical analysis was per-
ormed using GraphPad Prism 7.03a, (RRID: SCR 002798). p < .05
as considered statistically signiﬁcant. The individual statistical
ests are separately indicated in the ﬁgure legends. 
. Results 
.1. SPARC is expressed early during PanIN development, mediates 
ollagen deposition but does not affect PanIN-PDAC progression 
To investigate the effects on ECM formation, PanIN progression
nd drug delivery upon oncogenic Kras G12D activation, we crossed
PARC −/ − mice (B6;129S-Sparc tm1Hwe /J) with KC mice to obtain KC-
PARC −/ − and KC- SPARC WT control mice. Germline SPARC ablation
id not impair normal pancreas development and weight ( Fig. 1 A,
). In analogy to humans, immunohistochemistry revealed no ex-
ression in healthy pancreas tissue, whereas SPARC was expressed
n activated ﬁbroblasts around PanINs and in the tumour stroma of
nvasive murine PDAC ( Fig. 1 C). 
Subsequently, we separated both KC- SPARC −/ − and KC- SPARC WT 
ice into two cohorts to assess the role of SPARC during differ-
nt stages of PanIN progression: early ADM and PanIN progression
3–4 months old, n ≥7 mice per cohort), and advanced PanIN le-
ions (7–8 months old, n ≥8 mice per cohort) ( Fig. 1 D). Notably,
PARC ablation resulted in a dramatic reduction in overall and ma-
ure collagen ( Fig. 1 E, F; p < .001). 
In line with immunohistochemistry, isolation of ﬁbroblasts and
pithelial cells from advanced PanIN lesions from both genotypes
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Fig. 1. A: Representative H&E stainings of 10 months old SPARC −/ − mice and control wildtype mice show normal histological architecture of the pancreas. B: Pancreas weight 
of SPARC −/ − mice ( n = 6) and control wildtype mice ( n = 6)( p = .1, Mann-Whitney- U test). C: SPARC immunohistochemistry in KC- SPARC WT mice shows robust expression in 
ﬁbroblasts around PanINs (left upper panel) and cancer associated ﬁbroblasts (right upper panel). Lower panel reveals no immunoreactivity for SPARC in KC- SPARC −/ − mice. 
D: H&E stainings of KC- SPARC WT and KC- SPARC −/ −mice from early and late PanINs. E: Masson trichrome (MT) and Herovici staining in pancreata from KC- SPARC WT and KC- 
SPARC −/ − reveals depletion of collagen matrix (blue), and reduction of mature collagen ﬁbres (red) in KC-SPARC −/ − mice (7–8 months). F: Automated quantiﬁcation of MT 
staining in KC- SPARC WT ( n = 7) and KC- SPARC −/ − ( n = 10) ( p < .001, Mann-Whitney-U test). (For interpretation of the references to colour in this ﬁgure legend, the reader is 
referred to the web version of this article.) 
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Fig. 2. A: Western blot analysis showing robust SPARC expression in isolated ﬁbroblasts from KC- SPARC WT with simultaneous collagen-I expression, whereas ﬁbroblasts from 
KC- SPARC −/ − and epithelial tumour cells are devoid of SPARC expression ( n = 2 for each cell line). KC- SPARC −/ − ﬁbroblasts express collagen as SPARC is not involved in collagen 
synthesis but assembly and deposition. B, C: Semiquantitative analysis (score 0–3) of early (3–4 months old) and late (7–8 months old) ADM and PanIN I-II lesions in KC- 
SPARC WT ( n = 7/8) and KC- SPARC −/- ( n = 10/11) mice. D: Immunohistochemistry for α-SMA and Ki67 in PanIN+ADM pancreatic tissue from KC- SPARC WT and KC- SPARC −/ −mice 
(3–4 months old). E: Automated quantiﬁcation of α-SMA immunohistochemistry in preneoplastic tissues from KC- SPARC WT and KC- SPARC −/ − mice (3–4 months old). F: Manual 
quantiﬁcation of Ki67 immunohistochemistry showing no signiﬁcant differences between KC- SPARC W T and KC- SPARC −/ −mice (3–4 months old). G: Automated quantiﬁcation 
of CD31 immunohistochemistry in preneoplastic tissues from KC- SPARC WT ( n = 7) and KC- SPARC −/ − ( n = 10) mice (3–4 months old, p -values all calculated by Mann-Whitney- U 
test). 
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p n = 2 for each genotype) showed no expression of SPARC in ep-
thelial cells, and strong expression in ﬁbroblasts derived from KC-
PARC WT ( Fig. 2 A). Comparable results were obtained from a set of
uman PDAC cell lines and PSCs by Western blot analysis ( Suppl
ig. 1 A). 
In line with immunohistochemistry, isolation of ﬁbroblasts and
pithelial cells from advanced PanIN lesions from both genotypes
 n = 2 for each genotype) showed no expression of SPARC in ep-
thelial cells, and strong expression in ﬁbroblasts derived from KC-
PARC WT ( Fig. 2 A). Comparable results were obtained from a set of
uman PDAC cell lines and PSCs by Western blot analysis (Suppl
ig. 1A). 
Notably, as SPARC regulates collagen deposition in vivo, but not
ollagen secretion, collagen levels were comparable between the
wo genotypes in cultured ﬁbroblasts ( Fig. 2 A). 
Semi-quantitative pathological scoring (0–3) revealed no signif-
cant differences in ADM and PanIN progression upon SPARC de-
letion at both time points ( Fig. 2 B, C). 
Additional immuno-histochemical analysis showed no signiﬁ-
ant changes in α-SMA positive ﬁbroblasts or overall prolifera-
ion rate ( Fig. 2 D–F). Moreover, mean vessel density (CD31) was
nchanged in PanINs and ADMs upon SPARC ablation ( Fig. 2 G).
his is in contrast to previous data where lack of SPARC en-
anced vascular function in an orthotopic mouse model of PDAC
 19 ]. .2. SPARC ablation signiﬁcantly reduces survival in the KC mouse 
odel and reveals increased frequency of tumour related symptoms 
In order to investigate the effects of peritumoural SPARC as
arker for the “activated” tumour stroma, we aged KC- SPARC −/ −
 n = 53) and KC- SPARC WT control mice ( n = 29) for > 12 months.
umour development mostly occurred after 12 months (range 5–
1 months). Tumour frequency in both cohorts was not signiﬁ-
antly different for KC-SPARC −/ − and KC-SPARC WT mice (49% vs.
5%, Fig. 3 A). Tumour related survival was deﬁned according to es-
ablished endpoint criteria such as ascites, inactivity, jaundice, and
igniﬁcant weight loss. In a separate survival cohort, tumour bear-
ng KC- SPARC −/ − ( n = 25) showed a signiﬁcantly shortened survival
rom birth compared to tumour bearing KC- SPARC WT mice ( n = 16;
80d vs 485d, p < .03, Log-rank test, Fig. 3 B). Tumour tissue was
nalysed regarding ECM formation and showed a dramatic reduc-
ion in collagen content and organization ( Fig. 3 C–E). 
However, SPARC nullizygosity neither affected the proportion of
-SMA positive ﬁbroblasts nor intratumoural hyaluronic acid ac-
umulation ( Fig. 3 F, Suppl Fig. 1 B, C). Furthermore, tumour pro-
iferation and apoptosis rate were not signiﬁcantly changed be-
ween the two cohorts of mice ( Suppl Fig. 1 D, E). All tumours were
raded from G1-G4 with the majority of tumours being G2 for KC-
PARC −/ − (13/23; 57%) and KC-SPARC WT (10/18; 56%) and no ap-
arent association of SPARC expression and differentiation. 
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Fig. 3. A: PDAC frequency in KC- SPARC WT ( n = 29, 65% tumour frequency) and KC- SPARC −/ − ( n = 53; 49% tumour frequency, p = .1, Fishers Exact test). B: Survival analysis of 
tumour bearing KC- SPARC WT ( n = 16) and KC- SPARC −/ − ( n = 25) mice shows signiﬁcantly reduced survival of KC-SPARC −/ −mice (280 days versus 485 days, p = .02, log-rank-test). 
C: Masson trichrome (MT) and picrosirius red staining in pancreatic tumours derived from KC- SPARC WT and KC- SPARC −/ −mice shows reduced overall collagen, in particular 
collagen I and III (picrosirius red). D: Automated quantiﬁcation of MT in tumours from KC- SPARC WT ( n = 8) and KC- SPARC −/ − ( n = 17) mice ( p < .05, Mann Whitney U test) 
E: Automated quantiﬁcation of picrosirius red in tumours from KC- SPARC WT ( n = 7) and KC- SPARC −/ − ( n = 18) mice. Collagen is signiﬁcantly reduced in KC-SPARC −/ − mice 
( p = .01; Mann Whitney U test). F: Automated quantiﬁcation of α-SMA immunohistochemistry in tumours from KC- SPARC WT ( n = 8) and KC- SPARC −/ − ( n = 16) mice ( p = .7, 
Mann-Whitney-U test). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.) 
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d  However, SPARC nullizygosity neither affected the proportion of
α-SMA positive ﬁbroblasts nor intratumoural hyaluronic acid ac-
cumulation ( Fig. 3 F, Suppl Fig. 1B, C). Furthermore, tumour pro-
liferation and apoptosis rate were not signiﬁcantly changed be-
tween the two cohorts of mice (Suppl Fig. 1D, E). All tumours were
graded from G1-G4 with the majority of tumours being G2 for KC-
SPARC −/ − (13/23; 57%) and KC-SPARC WT (10/18; 56%) and no ap-
parent association of SPARC expression and differentiation. 
3.3. Clinical symptoms are more severe in KC-SPARC −/ − mice, but 
frequency of liver metastasis is not affected by SPARC ablation 
Since macrophage derived SPARC was shown to be involved in
metastasis formation using an orthotopic model [ 32 ], we quanti-
ﬁed micro- and macro-metastases to the liver, however, no sig-
niﬁcant difference was observed upon SPARC depletion ( Fig. 4 A,
B). Notably, clinical symptoms such as ascites, jaundice and diar-
rhoea occurred more frequently in KC- SPARC −/ − ( Table 1 ), provid-
ing a possible explanation for the shortened survival despite the
comparable tumour kinetics. Table 1 
Clinical symptoms in KC- SPARC WT ( n = 18) and KC- SPARC −/ −
( n = 26) mice showing a more severe phenotype in KC- SPARC −/ −
mice. 
Clinical signs KC- SPARC −/ − ( n = 26) KC- SPARC WT ( n = 18) 
Ascites 4 (15%) 0 
Jaundice 4 (15%) 1 
Diarrhoea 2 (8%) 0 
p -values for ascites ( p = .1), jaundice ( p = .6), and diarrhoea 
( p = .5) using Fishers Exact test. 
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a  .4. SPARC ablation and subsequent collagen reduction in murine 
DAC does not impair gemcitabine delivery or immediate eﬃcacy 
Since SPARC was suggested as negative predictive factor for
he treatment with gemcitabine [ 16 ], we investigated whether
PARC dependent collagen deposition would impinge on gem-
itabine metabolism and effectiveness. To this end, we treated
umour-bearing 12–15 months old KC- SPARC −/ − ( n = 10) and KC-
PARC WT mice ( n = 6) with a single dose of 100 mg/kg gemcitabine.
ancreatic tumour samples were taken 2 h after gemcitabine ad-
inistration as previous data had shown that peak gemcitabine
evels and gemcitabine induced cell death were reached after 2 h
 25 ]. 
Tumour samples were subjected to LC-MS/MS analysis and
howed no signiﬁcant differences for the gemcitabine prodrug
 
′ ,2 ′ -diﬂuorodeoxycytidine (dFdC) as well as for the activated
nd cytotoxic form of gemcitabine 2 ′ ,2 ′ -diﬂuorodeoxycytidine-5 ′ -
riphosphate (dFdCTP) despite the differences in collagen content
 Fig. 4 C, D). Furthermore, the immediate therapeutic response did
ot differ between KC- SPARC −/ − and KC- SPARC WT tumours as evi-
enced by a comparable number of cleaved-caspase 3 positive tu-
our cells ( Fig. 4 E). 
. Discussion 
PDAC is characterised by the accumulation of large amounts of
CM components such as collagen and hyaluronic acid, as well as
bundant ﬁbro-inﬂammatory cells that surround neoplastic cells at
arge numbers. Over the last years, accumulating evidence suggests
hat the tumour stroma can both restrain and promote disease
rogression and therapeutic resistance [ 7, 33, 34 ]. However, due to
he complex composition of cellular and acellular components of
he stroma, it is often not clear which components accelerate and
ttenuate tumour progression. Furthermore, a highly debated and
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Fig. 4. A: H&E staining from micro-metastases (circles left picture) and macro-metastases of the liver in KC-SPARC WT mice. B: Manual quantiﬁcation of macro- and 
micro-metastases in KC-SPARC WT ( n = 10) and KC-SPARC −/ − ( n = 15). C + D Tumour tissues from KC- SPARC WT ( n ≥5) and KC- SPARC −/ − mice ( n = 10) were assessed for gem- 
citabine metabolites 2 h after injection of 100 mg/kg gemcitabine by LC-MS/MS. Native gemcitabine (dFdC) and the active form of gemcitabine 2 ′ ,2 ′ -diﬂuorodeoxyuridine- 
5 ′ -triphosphate (dFdCTP) were not signiﬁcantly altered between the two genotypes. E: Manual quantiﬁcation of CC3 immunohistochemistry in tumours from KC- SPARC WT 
( n = 6) and KC- SPARC −/ − ( n = 6) mice upon 1 dose of gemcitabine at 100 mg/kg. Mann-Whitney-U test was used for calculation of p -values. 
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targely unsolved question is whether this desmoplastic reaction in
DAC creates biophysical barriers for drug delivery that may, at
east partly, explain the highly chemoresistant phenotype of hu-
an PDAC. Consequently, despite several promising preclinical ap-
roaches to therapeutically target the tumour stroma [ 5–8 , 10, 25 ],
one of the anti-stromal compounds have so far succeeded in clin-
cal trials [ 4 ]. Stromal and epithelial subtyping conducted by RNA
equencing and often combined with laser capture microdissection
as recently revealed “activated” and “normal” stromal subtypes in 
DAC patients that are strongly correlated with prognosis [ 13, 35 ].
he fact that SPARC is one of the most prominently expressed tran-
cripts in the “activated” stroma subtype that is correlated with
orse survival [ 13 ], and the fact that SPARC was suggested as po-
ential biomarker for gemcitabine response [ 16 ], led us to inves-
igate the expression, function and preclinical relevance of peritu-
oural SPARC in a genetically engineered mouse model of PDAC. 
Therefore, we depleted the matricellular protein SPARC that is
entrally involved in collagen maturation and deposition in the
C mouse model to investigate the effect of SPARC on the PanIN-
DAC progression. Notably, our results show that SPARC ablation
aused a signiﬁcant reduction in overall and mature collagen de-
osition during preneoplastic and invasive tumour stages. Despite
he fact that tumour bearing KC- SPARC −/ − mice lived signiﬁcantly
horter compared to their tumour bearing wildtype littermates,
allmark features such as PanIN progression, epithelial cell prolif-
ration, CAF viability, and invasiveness, angiogenesis or metastatic
requency were not altered by SPARC expression. Thus, the short-
ned survival may likely be caused by an increase in tumour re-
ated symptoms such as ascites, diarrhoea and jaundice, but not by
ore aggressive and metastatic tumours per se. This more severe
henotype might be caused by systemic effects of global SPARC
epletion in mice upon tumour induction, but not speciﬁcally by
lterations of stromal SPARC ablation in pancreatic tumours. Al-
eit not signiﬁcantly, it was interesting to note that despite theorse outcome of KC- SPARC −/ − mice, tumour frequency was lower
n KC- SPARC −/ − compared to KC- SPARC WT mice . Conditional genetic
eletion of SPARC using a ﬁbroblast-speciﬁc promoter such as α-
MA or collagen should be performed and might yield distinctly
ifferent results. Previous data generated in orthotopic and ge-
etically engineered mice (LSL-Kras G12D ; Cdkn2a lox/lox ; p48 Cre ) sug-
est direct effects of SPARC on angiogenesis and tumour progres-
ion that could not be recapitulated in our experiments using the
C-mouse model [ 17, 19 ], where ADM and PanIN lesions slowly
rogress, and tumour development occurs only in about 50–60% of
ice. These fundamentally different growth kinetics and the more
ggressive tumour biology using LSL-Kras G12D ; Cdkn2a lox/lox ; p48 Cre 
ice may have determined the observed phenotype. 
Since SPARC was suggested as negative predictive factor for
he treatment with gemcitabine [ 16 ], we investigated whether
PARC dependent collagen deposition would impinge on gemc-
tabine metabolism and effectiveness for the ﬁrst time. In line with
reviously published data on nab-paclitaxel and SPARC [ 30, 36, 37 ],
e did not see signiﬁcant changes in gemcitabine pharmacokinet-
cs and pharmacodynamics upon genetic SPARC modiﬁcation. 
Therefore, our data suggest that despite the observed collagen
eduction, peritumoural SPARC ablation neither determines hall-
ark features of pancreatic tumour development and progression
or the response to gemcitabine in a genetically engineered model
f autochthonous PDAC. However, one potential limitation of our
ouse model is that SPARC was deﬁcient in all cells during de-
elopment thus potentially affecting the results and the phenotype
f the mice. Notably, two major cell types of the TME, CAFs and
umour-associated macrophages (TAMs) were recently discovered
o actively metabolise and scavenge chemotherapeutic drugs in ex-
erimental PDAC [ 11, 38 ]. Our current ﬁndings on SPARC dependent
ollagen deposition and gemcitabine delivery are in line with these
ata and point towards a critical role of these cell types for future
herapeutic approaches and clinical trial design. 
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